The co-occurrence of KEAP1 and KRAS mutations suggests that KEAP1 mutations either affect NRF2 activity differently than KRAS-stimulated overexpression of NRF2, or are affecting other signalling pathways that are beneficial to the tumour. This evidence concerns the gene NFE2L2 and neoplasm.